DERMATOLOGISTS' CASE FILES
Managing Premalignant Skin Disorders

A supplement to Skin & Allergy News, supported by a restricted educational grant from 3M Pharmaceuticals and designated by the American Academy of Dermatology (AAD) for AAD continuing medical education (CME) credit.

•Topics
•Faculty
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above.

Topics

• Management of Actinic Keratosis and Malignant Skin Lesions
• Management of Actinic Keratosis
• Challenges of Lentigo Maligna
• Topical Therapy for Cutaneous Metastatic Melanoma

Faculty

Christopher B. Zachary, MBBS, FRCP
Professor and Chair
Department of Dermatology
University of California at Irvine
Dr. Zachary has received funding for clinical grants from and is a speaker for Candela Laser GmbH, Iridex Corporation, Reliant Pharmaceuticals, and Sciton, Inc. He is also a consultant to Ferndale Laboratories, Inc., and SkinMedica.

Mitchell E. Stashower, MD
The Clinical Skin Center of Northern Virginia, Fairfax
Assistant Professor of Dermatology
Uniformed Services University of Health Sciences
Bethesda, Md.
Dr. Stashower is a speaker, consultant, and investigator for 3M.

M. Shane Chapman, MD
Associate Professor of Medicine (Dermatology)
Dartmouth-Hitchcock Medical Center
Lebanon, N.H.
Dr. Chapman has received funding for clinical grants from and is a consultant to 3M Pharmaceuticals. He discusses the unlabeled use of imiquimod for the treatment of lentigo maligna.

Target Audience

This educational activity has been developed for dermatologists and other health care providers involved in the care of patients who present with skin lesions that have malignant potential.

Educational Needs

A widespread lax approach to prevention of sun-induced skin problems continues to send millions of patients to dermatologists' offices for evaluation and treatment of premalignant and malignant skin lesions. Actinic keratosis alone accounts for 47 million dermatologist office visits annually. Surgical and destructive or abrasive therapies represent the primary approach to treatment of premalignant and malignant skin lesions. Topical agents have had only a minor role in the management of these lesions, aside from topical 5-fluorouracil, which many patients find difficult to tolerate. Development of effective, better-tolerated, topical agents potentially could have a major impact on the approach to management of conditions such as actinic keratosis, lentigo maligna, and cutaneous metastatic melanoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Recognize common skin lesions that have malignant potential.

• Describe current approaches to treatment of premalignant and malignant skin lesions.

• Understand the role of nonsurgical, nondestructive therapies.

• Appreciate the therapeutic potential of effective, well-tolerated topical agents for treatment of premalignant and malignant skin lesions.

CME Recognition

This Skin & Allergy News supplement is recognized by the American Academy of Dermatology (AAD) for 1 hour of AAD Category 1 CME credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.

This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines.

Term of Approval: September 2006-August 31, 2007.

Copyright © 2006 Elsevier Inc.

---